[Form 4] Co-Diagnostics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Co-Diagnostics insider Richard David Abbott received 220,000 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2015 Long Term Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. After the grant Abbott beneficially owns 350,438 shares of common stock, with the 220,000 RSUs vesting in six installments beginning 11/23/2025 and continuing every six months thereafter. The Form 4 was signed 08/15/2025 and lists Abbott as President and a director.

Positive

• 220,000 RSUs granted under the Issuer's 2015 Long Term Incentive Plan, explicitly stated in the filing
• Each RSU converts to one share upon vesting, as described in the document
• Post-grant beneficial ownership disclosed: 350,438 shares are reported following the transaction

Negative

• None.

Insights

Financial Analyst

TL;DR: A routine executive equity grant increases the reporting person’s potential stake by 220,000 RSUs, vesting over three years.

The filing documents a standard equity compensation grant to the company President under the 2015 Long Term Incentive Plan. The RSUs convert one-for-one into common shares upon vesting and raise reported beneficial ownership to 350,438 shares. The staggered vesting schedule beginning 11/23/2025 implies retention incentives tied to future service rather than immediate dilution. No cash exercise price is reported.

Corporate Governance Expert

TL;DR: Disclosure shows a clear, plan-based RSU grant to a named officer with defined vesting dates; disclosure appears complete and routine.

This Form 4 specifies the grant source, unit-to-share conversion, and a six-installment vesting timetable, meeting typical Section 16 disclosure requirements. The report identifies Abbott s roles and provides the post-grant beneficial ownership total. There are no amendments, derivative transactions, or peculiar transfer arrangements disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abbott Richard David

(Last) (First) (Middle)

C/O CO-DIAGNOSTICS, INC.

2401 S. FOOTHILL DRIVE, SUITE D

(Street)

SALT LAKE CITY UT 84109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Co-Diagnostics, Inc. [ CODX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/13/2025		A		220,000		(2)	(2)	Common Stock	130,438	$0.00	350,438	D

Explanation of Responses:

1. Granted pursuant to Issuer's 2015 Long Term Incentive Plan, as amended. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's common stock.

2. RSU vests in 6 installments commencing on 11/23/25 and continues every 6 months thereafter.

Remarks:

	Richard David Abbott	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Co-Diagnostics (CODX) report on the Form 4 for Richard David Abbott?

The Form 4 reports a grant of 220,000 restricted stock units (RSUs) to Richard David Abbott on 08/13/2025.

How many shares does Abbott beneficially own after the reported transaction?

Following the reported transaction Abbott beneficially owns 350,438 shares of common stock.

What is the vesting schedule for the RSUs granted to Abbott?

The RSUs vest in 6 installments commencing on 11/23/2025 and continue every six months thereafter.

Under what plan were the RSUs granted?

The RSUs were granted pursuant to the Issuer's 2015 Long Term Incentive Plan, as amended.

Does the filing show a cash price for the RSUs or any exercise price?

No cash or exercise price is reported; the filing shows the RSUs convert to common stock with a reported price of $0.00 for the underlying shares.